Business Context and Reporting Period
This Form 8-K is a current report filed by Ekso Bionics Holdings, Inc. (not Chronoscale Holdings Corp as indicated in metadata) on June 10, 2015. The filing covers events occurring on June 10 and June 11, 2015, specifically regarding executive compensation arrangements and the results of the annual stockholder meeting.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. It references performance targets related to unit shipments, unit orders, and revenue targets for engineering services but does not disclose actual financial results for the period.
Material Changes and Executive Compensation
The Compensation Committee approved a 2015 Short Term Incentive Plan and granted stock options to key executives:
- Cash Bonus Targets: CEO Nathan Harding (60% of base salary); CFO Max Scheder-Bieschin and President Thomas Looby (40% of base salary); President of Ekso Labs Russ Angold (30% of base salary).
- Performance Goals: Bonuses are weighted based on Financial (unit shipments/orders/revenue), Strategic (gross margin/reimbursement/clinical studies), and Tactical (regulatory/product roadmap/cost) goals.
- Stock Option Grants (June 11, 2015):
- Nathan Harding: 500,000 shares
- Max Scheder-Bieschin: 313,000 shares
- Thomas Looby: 600,000 shares
- Russ Angold: 700,000 shares
- Vesting Terms: Options for Harding, Scheder-Bieschin, and Looby vest over four years (25% annually). Angold's options vest in three tranches contingent on achieving confidential revenue targets for the industrial business between 2016 and 2017.
Stockholder Meeting Results
At the Annual Meeting held on June 10, 2015, stockholders voted on three proposals:
| Proposal | For | Against/Withheld | Abstain | Broker Non-Votes |
|---|---|---|---|---|
| Election of 7 Directors | Varied (e.g., 42.3M for Harding) | Varied (e.g., 305k withheld for Harding) | N/A | 20,917,779 |
| Ratification of 2014 Equity Incentive Plan | 41,487,357 | 697,269 | 416,405 | 20,917,779 |
| Ratification of Auditor (OUM & Co.) | 62,186,273 | 730,122 | 602,415 | 0 |
All proposals were approved. Notably, there were significant broker non-votes on the director election and equity plan ratification.
Outlook and Risks
Management commentary indicates that the industrial exoskeleton business is considered "emerging," necessitating performance-based vesting for the President of Ekso Labs. The Compensation Committee retains discretion to adjust awards based on company cash resources as of December 31, 2015.
Investor Verification Checklist
- Verify the discrepancy between the metadata company name (Chronoscale Holdings Corp) and the filing registrant (Ekso Bionics Holdings, Inc.).
- Review the specific confidential revenue targets required for Russ Angold's option vesting in the industrial sector.
- Assess the impact of the 2015 Short Term Incentive Plan on future cash burn relative to the company's cash resources.
- Confirm the total outstanding share count to evaluate the dilution impact of the 2.113 million new options granted.